AlphAIalphai — Financial news for AI agents
quiverquant.comSEP 23 min read$RVMD

Revolution Medicines Announces NEJM Publication of Phase 1/2 RASONQUE Data Supporting Ongoing Phase 3 RASolve 301 Trial in RAS Mutant NSCLC

Revolution Medicines (RVMD) announced NEJM publication of Phase 1/2 trial data for RASONQUE (daraxonrasib) in RAS mutant NSCLC. The trial showed 42% objective response rate and 89% disease control rate in a subgroup, with manageable safety profile. The data support the ongoing Phase 3 RASolve 301 trial, following recent FDA approval for pancreatic cancer.

Original reporting
quiverquant.com
Published Sep 2, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Revolution Medicines Announces NEJM Publication of Phase 1/2 RASONQUE Data Supporting Ongoing Phase 3 RASolve 301 Trial in RAS Mutant NSCLC — source image
Source · quiverquant.com
Decision brief

The 30-second read

$RVMDBullishHigh
01

Why it matters

The data provide clinical validation for the ongoing Phase 3 RASolve 301 trial, likely influencing RVMD valuation and investor sentiment.

02

Market read

First‑time disclosure of promising early‑stage trial results for a novel oncology asset; potential catalyst for RVMD and related biotech stocks.

03

What to watch

Safety profile shows 25% Grade 3 TRAEs; competitive landscape includes other RAS inhibitors.

Relevance 9/10Novelty 9/10Timing: published Sep 2 2026 (same‑day release)

Background

Revolution Medicines announced NEJM publication of Phase 1/2 data for its oral RAS inhibitor RASONQUE in RAS‑mutant NSCLC, following FDA approval in pancreatic cancer.

Company-level read

Ticker impact

$RVMDBullishHigh confidence
Context

NEJM published Phase 1/2 trial data for RASONQUE showing 42% response rate and 8.3‑month PFS in RAS‑mutant NSCLC patients.

Expected impact

upward pressure, potential 10‑15% rally ahead of Phase 3 results.

Evidence & confidence

Objective response and disease‑control rates are strong for a non‑G12C RAS indication; the trial supports the ongoing pivotal study, likely attracting buy‑side interest.

Market effects

Sector

Strengthens outlook for RAS‑targeted oncology sector and may lift peer biotech stocks.

Regional

U.S. biotech market could see modest gains; limited immediate effect on broader indices.

Global

Highlights progress in targeted cancer therapies, relevant to global oncology investors.

Counterpoint

What could challenge this read

Data are early‑stage; Phase 3 may not replicate results, risk of overvaluation.

Key entities

  • Company
    Revolution Medicines, Inc.

    Biotech firm developing RAS‑targeted therapies (ticker RVMD).

  • Drug
    RASONQUE (daraxonrasib)

    Oral multi‑selective RAS inhibitor under investigation for NSCLC and pancreatic cancer.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 4
$RVMDHighAI 8/10

Michael Osterholm Says He's Staying Four More Years as Public Health's Systems Buckle — BigGo Finance

Revolution Medicines' FDA-approved cancer drug, divarasib and razabi, targets RAS protein, previously deemed undruggable. CEO Mark Goldsmith bet the company on this target, leading to a successful Phase 3 trial. Michael Osterholm, 73, delayed retirement to address public health challenges, launching the Vaccine Integrity Project. David Baker, Nobel laureate, focuses on designing novel proteins and mentoring scientists.

finance.biggo.com2 min
SEP 3
$RVMDHighAI 9/10

Daraxonrasib shrinks tumours in one-third of lung cancer patients

Revolution Medicines Inc. (RVMD) reported that its experimental drug daraxonrasib shrank tumors in 33% of advanced lung cancer patients in a Phase 1/2 trial, with symptom improvements. The study, published in the New England Journal of Medicine, involved 136 patients with RAS gene mutations. The drug targets multiple RAS mutations and showed a median response duration of 11.5 months. Side effects were common, with rash, diarrhea, and nausea affecting many patients. The company is now conducting

mugglehead.com2 min
SEP 3
$RVMDMedAI 8/10

RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer

Revolution Medicines (RVMD) presented updated Phase 1/2 trial data for Rasonque in non-small cell lung cancer (NSCLC), showing a 42% overall response rate, 8.3-month median progression-free survival, and 16-month median overall survival. Truist Securities noted the results support RVMD's Phase 3 lung cancer study. Rasonque was recently FDA-approved for pancreatic cancer, with Phase 3 results expected in December 2027 for NSCLC.

biospace.com2 min
SEP 3
$RVMDMedAI 8/10

NEJM publishes daraxonrasib NSCLC data supporting Phase III program

Revolution Medicines (RVMD) published Phase I/II data in NEJM showing daraxonrasib's antitumor activity in RAS-mutant NSCLC. The study reported a 42% response rate and 8.3-month median progression-free survival. The company is advancing the drug in a Phase III trial. Daraxonrasib was recently approved for pancreatic cancer, marking the company's first commercial product.

allsci.com2 min
SEP 2
$RVMDMedAI 9/10

RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM

Revolution Medicines (RVMD) announced the publication of Phase 1/2 trial results for RASONQUE in the New England Journal of Medicine. The data showed promising efficacy and safety in treating advanced RAS mutant NSCLC. The company has a market cap of $44.85 billion and is currently unprofitable, with a high Price-to-Sales ratio of 70.5x. Insider activity shows significant selling, while guru ownership trends are mixed.

gurufocus.com3 min